What is HC Wainwright's Estimate for uniQure Q3 Earnings?

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for uniQure to a loss of ($0.73) per share, improving from a prior estimate of ($0.75), while maintaining a "Buy" rating and a $70.00 price target.
• Most analysts hold a Moderate Buy consensus on uniQure's stock, with varying price targets that range from $28.00 to $47.00.
• uniQure reported a Q2 net loss of ($0.69) per share, exceeding analyst expectations, and achieved a revenue of $5.26 million against an estimate of $5 million.

uniQure N.V. (NASDAQ:QURE - Free Report) - HC Wainwright boosted their Q3 2025 earnings estimates for shares of uniQure in a report released on Wednesday, July 30th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of ($0.73) for the quarter, up from their prior estimate of ($0.75). HC Wainwright has a "Buy" rating and a $70.00 price target on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure's Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.04) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($2.12) EPS.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million.

A number of other equities research analysts also recently weighed in on the stock. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday. Chardan Capital set a $35.00 price target on shares of uniQure and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Cantor Fitzgerald set a $47.00 price target on shares of uniQure in a research note on Wednesday, July 30th. Finally, Guggenheim restated a "buy" rating and set a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and an average target price of $36.55.

uniQure Stock Up 0.3%

Shares of QURE stock traded up $0.04 on Friday, hitting $13.81. The company's stock had a trading volume of 844,500 shares, compared to its average volume of 1,418,938. uniQure has a fifty-two week low of $4.45 and a fifty-two week high of $19.18. The stock has a market capitalization of $757.97 million, a price-to-earnings ratio of -3.51 and a beta of 0.11. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The firm's fifty day moving average price is $14.83 and its 200-day moving average price is $13.68.

Institutional Investors Weigh In On uniQure

Institutional investors have recently added to or reduced their stakes in the business. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure in the 1st quarter worth approximately $106,000. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the 2nd quarter valued at $117,000. Teacher Retirement System of Texas bought a new stake in shares of uniQure in the 2nd quarter valued at $151,000. OMERS ADMINISTRATION Corp bought a new stake in shares of uniQure in the 1st quarter valued at $152,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at $177,000. 78.83% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other uniQure news, Director Madhavan Balachandran sold 2,112 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director directly owned 37,697 shares in the company, valued at $544,721.65. This represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert Gut sold 3,336 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the sale, the director owned 56,879 shares in the company, valued at approximately $821,901.55. The trade was a 5.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock valued at $322,426 in the last three months. Insiders own 4.79% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.